Author:
Qiang W.-G.,Shi L.-R.,Li X.-D.,Wu Q.-Q.,Zhao J.-M.,Chen L.-J.,Yang Y.,Wu J.,Ji M.,Wu C.-P.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Reference25 articles.
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi: 10.3322/caac.20107 .
2. Sperling J, Schafer T, Ziemann C, Benz-Weiber A, Kollmar O, Schilling MK, et al. Hepatic arterial infusion of bevacizumab in combination with oxaliplatin reduces tumor growth in a rat model of colorectal liver metastases. Clin Exp Metastasis. 2012;29(2):91–9. doi: 10.1007/s10585-011-9432-6 .
3. Teker F, Demirag G, Erdem D, Kemal Y, Yucel I. Quality of life in colorectal cancer patients during chemotherapy in the era of monoclonal antibody therapies. J BUON. 2015;20(2):443–51.
4. Klaver CE, Musters GD, Bemelman WA, Punt CJ, Verwaal VJ, Dijkgraaf MG, et al. Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial. BMC Cancer. 2015;15(1):428. doi: 10.1186/s12885-015-1430-7 .
5. Landry JC, Feng Y, Prabhu RS, Cohen SJ, Staley CA, Whittington R, et al. Phase II trial of preoperative radiation with concurrent Capecitabine, Oxaliplatin, and Bevacizumab followed by surgery and postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in patients with locally advanced rectal cancer: 5-year clinical outcomes ECOG-ACRIN cancer research group E3204. Oncologist. 2015. doi: 10.1634/theoncologist.2015-0106 .
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献